ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Deubiquitination of Vangl by USP6 and USP32 Regulates Planar Cell Polarity Signaling.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Planar cell polarity (PCP) signaling is an evolutionarily conserved mechanism regulating polarized cellular and tissue behaviors in diverse morphogenetic and physiological processes. Disruption or aberrant activation of PCP signaling can cause developmental defects or promote cancer malignancy. Vangl1 and Vangl2 are redundant core PCP components, and their protein levels are tightly controlled to maintain appropriate PCP signaling. Here, we identify two deubiquitinases, USP6 and USP32, that stabilize Vangl proteins through distinct ubiquitin linkage-specific mechanisms. USP6 primarily removes K33-linked and multi-monoubiquitin signals from plasma membrane-associated Vangl2, whereas USP32 removes K48-linked ubiquitin chains from Golgi/ER-localized Vangl2, thereby regulating distinct subcellular pools of Vangl2. Given that USP6 was previously reported to be a hominoid-specific gene originating from USP32, our findings suggest evolutionary refinement in PCP regulation. Consistent with these biochemical functions, genetic interaction studies demonstrate that Usp32 cooperates with Vangl genes to regulate PCP signaling during mouse embryogenesis. In pancreatic ductal adenocarcinoma, USP32 and VANGL1 are markedly upregulated and functionally promote cancer cell migration and metastasis. USP32 enhances metastatic behavior by stabilizing VANGL1 proteins. Together, our findings uncover a previously unrecognized regulatory mechanism of PCP signaling through USP6/USP32-mediated deubiquitination of Vangl proteins and highlight its roles in both developmental morphogenesis and cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.